Sermorelin: what the research says.
Last updated May 22, 2026
More: Clinical standards · Pharmacy partners
A growth-hormone-releasing hormone (GHRH) analog studied for decades, originally as a diagnostic for pediatric GH deficiency, more recently for adult recovery and body-composition goals. Here’s what the evidence supports, and what it doesn’t.
What sermorelin is.
Sermorelin is a synthetic 29-amino-acid peptide, the first 29 residues of endogenous growth hormone-releasing hormone (GHRH). It was developed in the 1980s and, under the brand name Geref, received FDA approval for the diagnosis and treatment of growth hormone deficiency in children. Geref was discontinued from commercial brand-name production in 2008.
Today, sermorelin is primarily accessed through licensed US compounding pharmacies under the federal 503A framework. Adult use, for recovery, sleep quality, and body composition, is off-label; GHRH therapy was never FDA-approved for those indications.
Because sermorelin acts upstream of the pituitary gland, it is fundamentally different from synthetic exogenous human growth hormone (recombinant hGH). Sermorelin prompts a natural, pulsatile release of endogenous GH; recombinant hGH bypasses that feedback loop entirely. The distinction matters for both efficacy expectations and side-effect profile.
How it works
Mechanism of action.
Binds GHRH receptors on somatotrophs
Sermorelin binds GHRH receptors on somatotroph cells in the anterior pituitary, triggering release of stored growth hormone into circulation. Because sermorelin uses the body's own pituitary machinery, the downstream GH response is subject to the normal hypothalamic-pituitary feedback loop, including somatostatin counterregulation.
Preserves natural GH rhythm
GH is normally secreted in pulses, with the largest pulse occurring during slow-wave sleep. Sermorelin's short half-life (roughly 10–20 minutes) means it amplifies existing pulses rather than generating a flat, sustained GH elevation. This rhythm-preserving mechanism is why sermorelin is typically dosed at bedtime.
Downstream liver response
GH released from the pituitary acts on the liver to produce insulin-like growth factor 1 (IGF-1), the mediator of many of GH's anabolic and metabolic effects. Sermorelin dosing is sometimes monitored via IGF-1 levels, which integrate GH exposure over hours and days.
Physiologic ceiling on GH
Because sermorelin works through the intact pituitary, somatostatin feedback limits how much GH can be released. This is a key pharmacological difference from recombinant hGH, which delivers supraphysiologic GH doses directly and can more easily produce adverse effects like fluid retention and insulin resistance at high doses.
The research landscape.
The published research base for sermorelin is smaller than for semaglutide or tirzepatide, and most high-quality data comes from the 1980s and 1990s when Geref was the active brand. Evidence for adult off-label use is mostly observational.
Pediatric growth hormone deficiency (historical)
Thorner and colleagues at the University of Virginia conducted foundational work on GHRH analogs, including sermorelin, in children with growth hormone deficiency (Thorner et al., Journal of Clinical Endocrinology & Metabolism, 1988 and onward). Sermorelin increased growth velocity in children with intact pituitary function and formed the basis for its FDA approval.
Adult GH axis and aging
Research by Corpas, Harman, and Blackman (National Institute on Aging; Journal of Clinical Endocrinology & Metabolism, 1992) showed that GHRH infusion could restore a more youthful GH pulse pattern in healthy older men, with modest increases in IGF-1. These studies support the pharmacological premise for adult use but don’t directly measure clinical outcomes like recovery or body composition.
Sleep quality
GHRH has an established role in slow-wave sleep regulation (Obal & Krueger, Sleep Medicine Reviews, 2004). Patients and clinicians often cite improved sleep depth on sermorelin, though randomized trial evidence specific to sermorelin and subjective sleep quality in adults is limited.
What research has not settled
Large-scale randomized trials of sermorelin for adult body composition, recovery, or longevity outcomes have not been conducted. Most adult-use evidence is observational, small, or extrapolated from the broader GH/IGF-1 literature. Readers should distinguish pharmacological rationale from proven clinical outcome.
What we know and don’t know.
- Activates pituitary GHRH receptors and raises endogenous GH pulses
- Raises IGF-1 in deficient patients at appropriate doses
- Short half-life and pulsatile action profile
- Tolerability profile well-characterized in pediatric use
- Long-term body-composition and performance outcomes in healthy adults
- Durability of sleep and recovery effects past 12 months
- Comparative effectiveness vs. other GH-pathway peptides
- Individual response variance and optimal dosing
Administration.
Sermorelin is administered by subcutaneous injection, typically daily and usually at bedtime to align with the body’s natural GH pulse cycle. Published protocols use doses roughly in the 100–500 mcg range; compounded pharmacy preparations and clinician dosing vary.
Because sermorelin’s half-life is very short (on the order of 10–20 minutes), the effect is a brief, amplified GH pulse rather than sustained elevation. Response is commonly monitored via IGF-1 levels drawn after several weeks of therapy.
This is research and regulatory context, not prescribing guidance. Your clinician will determine dosing based on your specific health profile.
Side effects & safety considerations.
Sermorelin’s safety profile has generally looked favorable in both historical pediatric studies and adult off-label use, but robust adult safety trials are limited.
Common side effects
Reported effects include mild injection-site reactions (redness, swelling, or discomfort), transient flushing, headache, and occasional lightheadedness around the time of dosing. These are typically mild and self-limiting.
Theoretical and long-term concerns
Any agent that elevates GH/IGF-1 carries theoretical concerns about effects on insulin sensitivity, fluid balance, joint pain (in susceptible individuals), and growth of existing neoplasms. The feedback-regulated nature of sermorelin's mechanism likely mitigates some of these risks relative to recombinant hGH, but long-term adult-use data is limited.
Contraindications
- •Active malignancy or history of hormonally responsive cancers
- •Pregnancy or breastfeeding
- •Known hypersensitivity to sermorelin or mannitol/preservatives used in preparation
- •Severe obesity (can blunt GH response)
- •Pituitary disorders may limit effectiveness or require alternative approaches
Your prescribing clinician will evaluate your medical history and health goals before determining whether sermorelin is appropriate. This page is educational, not medical advice.
Regulatory context.
Sermorelin previously had FDA approval under the brand name Geref for pediatric growth hormone deficiency. That brand was discontinued in 2008 for commercial reasons, not safety. Sermorelin itself remains a well-characterized molecule.
Compounded sermorelin is not FDA-approved. It is prepared on a patient-specific basis by US-licensed compounding pharmacies under the federal 503A framework. Adult use for recovery, sleep, or body composition is off-label; no sermorelin product is FDA-approved for those indications.
Sermorelin is a peptide and is not a banned substance in most jurisdictions, but it is on the World Anti-Doping Agency prohibited list for competitive athletes. Competing athletes should verify current WADA status before use.
Deep dives
More on Sermorelin.
Research-backed articles covering specific topics in depth.
Start a Sermorelin plan.
Three-minute assessment. Clinician review within 48 hours. You aren't charged unless sermorelin is prescribed.